Clinical trials: Steatosis
Hepatic Fat Accumulation, Nonalcoholic Fatty Liver Disease
Dietary Protein and Hepatic Fat Accumulation
The objective of this study is to investigate the potential beneficial effect of increasing protein in the diet in order to decrease hepatic lipid accumulation on a high-fat diet.
- Trial name
- LiF-Pro (NCT01354626)
- Testing
- dietary protein, low-protein
- Where
- Netherlands
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Wageningen University
Fat; Liver, NAFLD
The Effect of a High-fat vs. High-sugar Diet on Liver Fat Accumulation and Metabolism
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disease in the world. It is currently unclear why fat starts to accumulate in the liver, although both the amount and type of food consumed have been…
- Trial name
- NCT03145350
- Testing
- High-fat, low-carbohydrate, Low-fat, high-carbohydrate
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Non Alcoholic Fatty Liver Disease
Impact of Artificial Intelligence Algorithm-driven Versus Standard Lifestyle Intervention in Non-Alcoholic Fatty Liver Disease - A Multicenter, Randomized, Open-label, Controlled Trial
Now considered as a major public health challenge, non-alcoholic fatty liver disease (NAFLD) is rapidly rising as a major cause of end-stage liver disease.
- Trial name
- S@VE-LIVER (NCT07497750)
- Testing
- Fibroscan CAP/VTE, Randomization, MRI-PDFF
- Where
- 9 sites in France
- Volunteers
- 216 people
- Sponsor
- University Hospital, Toulouse
Fatty Liver
A Pilot Study to Explore the Role of Gut Flora in Fatty Liver
This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Fatty Liver.
- Trial name
- NCT04160949
- Testing
- No Intervention
- Where
- United States
- Sponsor
- ProgenaBiome
Non-alcoholic Fatty Liver Disease
Efficacy of Oral Trigonella Foenum-graecum Seed Extract Vs Placebo in Treatment of None Alcoholic Fatty Liver Disease
This study design to examine performance of trigonella foenum-graecum (TFG) in treatment of non-alcoholic fatty liver disease. Base on inclusion and exclusion criteria, 50 patients select and then randomize into intervention and…
- Trial name
- NCT02303314
- Testing
- Trigonella Foenum-graecum Seed Extract
- Where
- Iran
- Volunteers
- 35 people
- Sponsor
- Shiraz University of Medical Sciences
Nutrition, Healthy, Dietary Deficiency
Health Effects of Biostimulated Lettuce in Human
The aim of the project is to study the influence of biostimulate crops on a healthy population in order to assess influence on hematological parameters and specific metabolism (glucose, lipid, iron, bone) and gut and lipid…
- Conditions
- Nutrition, Healthy, Dietary Deficiency, Bone Resorption, Glucose Metabolism Disorders
- Trial name
- NUTRIWEED23 (NCT05971017)
- Testing
- Control Group, Biostimulated group
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Palermo
Type 2 Diabetes Mellitus, Obesity
The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes
This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in…
- Trial name
- TRIABETES (NCT01047735)
- Testing
- Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of Pittsburgh
Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis
Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors With Mazdutide (PRIME)
The purpose of this study is to evaluate the efficacy and safety of a short-term (12-week) prehabilitation strategy combining mazdutide (a novel GLP-1/GCG receptor dual agonist) with lifestyle optimization, compared to lifestyle…
- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis, Hepatic Steatosis, Living Liver Donors
- Trial name
- PRIME (NCT07718126)
- Testing
- Mazdutide, Lifestyle Optimization
- Where
- 4 sites in China
- Volunteers
- 60 people
- Sponsor
- West China Hospital
Fatty Liver, Fatty Liver, Nonalcoholic
Quantification of Hepatic Steatosis With Different Ultrasound Frequency
The objective of this study is: (1) to compare the feasibility (technical successes rate and reliability) in measuring attenuation coefficient between two different frequencies (3MHz, 4MHz) of ultrasound beam; (2) to evaluate and…
- Conditions
- Fatty Liver, Fatty Liver, Nonalcoholic, Ultrasound
- Trial name
- NCT05855239
- Where
- South Korea
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Jong Keon Jang
Steatohepatitis, Nonalcoholic
A Study to Assess the Safety, Efficacy, and Pharmacokinetics of Multiple Doses of ION224
The purpose of this study is to assess the effect of multiple ION224 doses when administered by subcutaneous (SC) injection for 49 weeks (end of the treatment [EOT]) on non-alcoholic steatohepatitis (NASH) histologic improvement…
- Trial name
- NCT04932512
- Testing
- ION224
- Where
- 51 sites in United States, Puerto Rico
- Volunteers
- 160 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease
Microbiome-Mediated Gut Dysfunction in Non-Alcoholic Fatty Liver Disease
This study is designed to generate the first human evidence to date on microbiota encroachment in non-alcoholic fatty liver disease.
- Trial name
- MODIFY (NCT05209100)
- Testing
- Sigmoidoscopy
- Where
- United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- AdventHealth Translational Research Institute
Nonalcoholic Fatty Liver Disease (NAFLD)
Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients
Nonalcoholic fatty liver disease (NAFLD) is the most common cause of abnormal liver biochemistry tests in the world. The prevalence rate of NAFLD has been reported to be 30-40% in men and 15-20% in women, up to 70% of people with…
- Trial name
- NCT04059029
- Testing
- Bariatric surgery
- Volunteers
- 200 people
- Sponsor
- Taipei Medical University Hospital
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, NAFLD - Non-Alcoholic Fatty Liver Disease
Development of a Quantifiable Ultrasound Biomarker for Hepatic Steatosis
The research study is considering a non-invasive way to measure the percentage of fat in the liver using ultrasound. This could help detect early signs of a very common condition called metabolic dysfunction-associated steatotic…
- Trial name
- LYNX (NCT07270601)
- Testing
- Verasonics NXT Data Acquisition System, Philips EPIQ Elite, EchoSense FibroScan
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- ContextVision AB
Non-Alcoholic Fatty Liver Disease, Cardiovascular Diseases
EndoNAFLD: Relationship Between Fatty Liver Disease and Cardiovascular Diseases
Management of risk factors is the primary approach to prevent cardiovascular disease (CVD). In this regard the accurate scoring of disease risk is fundamental.
- Trial name
- Endo-NAFLD (NCT06392828)
- Where
- 4 sites in Spain
- Volunteers
- 63 people
- Sponsor
- IMDEA Food
Non-Alcoholic Fatty Liver Disease
Liver Health and Metabolic Function in People With Obesity
This project aims to determine the effect of significant weight loss on rates on hepatic fibrogenesis in people with obesity.
- Trial name
- NCT03701828
- Testing
- Weight loss surgery
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Non Alcoholic Steatohepatitis
Fecal Microbiota Therapy Versus Standard Therapy in NASH Related Cirrhosis.
Patients of NASH (Non Alcoholic Steatohepatitis) cirrhosis with current or prior histological evidence of steatosis or steatohepatitis admitted under the Department of Hepatology at Institute of Liver and Biliary Sciences, who…
- Trial name
- NCT02721264
- Testing
- Fecal Microbiota Transplant, Standard Medical Treatment
- Where
- India
- Volunteers
- 112 people
- Sponsor
- Institute of Liver and Biliary Sciences, India
Pancreatic Exocrine Insufficiency
Screening for Pancreatic Exocrine Insufficieny in Metabolic Associated Fatty Liver Disease Patients
to investigate the frequency of PEI in MAFLD
- Trial name
- NCT05804409
- Testing
- FECAL ELASTASE
- Volunteers
- 70 people
- Sponsor
- Assiut University
Liver Transplant Rejection, Liver Transplant; Complications
Safety of DNP007 in Healthy Subjects
This clinical trial evaluated the safety, tolerability, pharmacokinetic properties, and immunogenicity of DNP007 when administered as a single dose.
- Conditions
- Liver Transplant Rejection, Liver Transplant; Complications, Steatohepatitis, Nonalcoholic
- Trial name
- NCT06400771
- Testing
- DNP007
- Where
- South Korea
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Nonalcoholic Steatohepatitis
A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
A Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 given by subcutaneous injection in adult participants with non-cirrhotic non-alcoholic steatohepatitis with fibrosis and who are carriers of the PNPLA3 148M…
- Trial name
- FORTUNA (NCT05809934)
- Testing
- AZD2693
- Where
- 163 sites in United States, Argentina and 20 more
- Volunteers
- 220 people
- Sponsor
- AstraZeneca
NAFLD, NASH
A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH
Double-blind, randomized, placebo-controlled study to explore the efficacy and safety of elobixibat compared to placebo in adults with NAFLD (nonalcoholic fatty liver disease) or NASH (nonalcoholic steatohepatitis)
- Trial name
- NCT04006145
- Testing
- Elobixibat
- Where
- 10 sites in United States
- Volunteers
- 47 people
- Sponsor
- Albireo
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.